MWNA
BMY.RT

Marshall Wace North America’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Marshall Wace North America’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,862,165
Closed -$3.97M – 1718
2020
Q3 		$4.19M Sell
1,862,165
-4,092,791
-69% -$11.7M 0.03% 430
2020
Q2 		$21.3M Buy
5,954,956
+880,440
+17% +$3.18M 0.14% 165
2020
Q1 		$19.3M Buy
5,074,516
+1,685,361
+50% +$5.55M 0.15% 157
2019
Q4 		$10.2M Buy
+3,389,155
New +$8.81M 0.05% 284

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Marshall Wace North America's BMY.RT Position: Q4 2020 in Review

Marshall Wace North America sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 1,862,165 shares — an estimated $3.97M sold.

Marshall Wace North America first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $21.3M in Q2 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Marshall Wace North America reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 1,862,165 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $3.97M.
  • Marshall Wace North America first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Marshall Wace North America's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $21.3M in Q2 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.